Global Leading Market Research Publisher QYResearch announces the release of its latest report “Urology Devices – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Urology Devices market, including market size, share, demand, industry development status, and forecasts for the next few years.
Solving the Silent Epidemic: Why Urology Devices Are Critical as Aging Populations Drive Urinary Disorder Prevalence
For healthcare systems worldwide, a quiet crisis is unfolding. Benign prostatic hyperplasia (BPH) affects over 50% of men aged 60 and above, urinary stone disease prevalence has doubled in the past two decades, and urological cancers (prostate, bladder, kidney) account for nearly 25% of new cancer diagnoses globally. The strain on hospital urology departments, operating rooms, and minimally invasive surgery centers is immense. Urology devices – endoscopic and imaging systems, surgical energy platforms, stone management tools, implants, and urodynamic equipment – are the frontline solution. These instruments enable less invasive procedures (shorter recovery, fewer complications) while managing rising patient volumes. According to Global Info Research’s latest modeling, the global market for Urology Devices was valued at US22,596millionin2024∗∗andisforecasttoreachareadjustedsizeof∗∗US22,596millionin2024∗∗andisforecasttoreachareadjustedsizeof∗∗US 30,670 million by 2031, growing at a CAGR of 4.3% from 2025 to 2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5444384/urology-devices
1. Market Segmentation and Product Categories
The urology devices market encompasses six major product segments, each with distinct dynamics.
Endoscopy and Imaging Systems represent the largest category (30-35% of revenue), including flexible and rigid cystoscopes, ureteroscopes, nephroscopes, and associated cameras and light sources. Karl Storz, Olympus, Richard Wolf, and Stryker dominate this capital equipment-intensive segment, with gross margins of 35-45%.
Surgical Energy and Resection Systems (20-25% of revenue) include laser systems (Holmium, Thulium) for stone fragmentation and prostate surgery, plasma kinetic (PK) resection devices, and bipolar electrosurgical units. Boston Scientific, Medtronic, and Olympus lead here. Laser systems have increasingly replaced traditional transurethral resection of the prostate (TURP), reducing hospital stays from 3-4 days to outpatient procedures.
Stone Management Devices (15-20% of revenue) comprise ureteral access sheaths, stone retrieval baskets, lithotripsy probes, and percutaneous nephrolithotomy (PCNL) instruments. This segment benefits from high procedure volumes (urinary stone disease prevalence 8-15% in developed nations) and high consumable turnover (single-use devices). Boston Scientific, Cook Medical, and Coloplast hold strong positions.
Implants and Functional Devices (10-15% of revenue) include artificial urinary sphincters (AMS 800 by Boston Scientific), male and female slings for stress incontinence, sacral neuromodulation systems (Medtronic’s InterStim), and prostatic urethral lifts (Teleflex’s UroLift). These are high-value, regulated implantables with gross margins of 50-65%.
Diagnostic and Urodynamic Equipment (5-10% of revenue) includes cystometers, flowmeters, and pressure transducers for assessing bladder function. Laborie, MEDpro Medical, and Allengers compete in this stable segment.
Other (consumables, catheters, guidewires) accounts for the remaining 5-10% and is dominated by BD, B. Braun, ConvaTec, and Hollister.
2. Market Growth Drivers (Last 6 Months)
Aging Demographics and Rising Disease Prevalence
The global population aged 65+ reached 800 million in 2025, projected to exceed 1 billion by 2030. BPH prevalence increases from 8% in men aged 31-40 to 80% in those over 80. Overactive bladder (OAB) affects 12-17% of adults over 60, while stress incontinence impacts 10-40% of women, particularly postpartum and postmenopausal. These demographics create steady, non-cyclical demand.
Minimally Invasive Procedures – The Shift from Equipment to Consumable Revenue
Hospitals are increasingly adopting disposable or single-use urology devices (endoscopes, lithotripsy probes, stone baskets) to eliminate cross-contamination risks and reduce sterilization costs. While capital equipment margins are 30-40%, disposable consumable margins reach 50-70%, creating a highly profitable recurring revenue model for manufacturers. Global Info Research analysis indicates that leading players now derive 60-65% of urology segment profits from consumables and service contracts, up from 40-45% a decade ago.
User Case – Boston Scientific’s Stone Management Growth (March 2026) : Boston Scientific reported that its single-use ureteroscope (LithoVue) franchise grew 22% year-over-year in Q1 2026, driven by U.S. and European hospitals shifting away from reusable scopes (which require expensive reprocessing and have high repair costs). The LithoVue single-use scope (950−1,200perprocedure)eliminatessterilizationcapitalequipment(950−1,200perprocedure)eliminatessterilizationcapitalequipment(150,000-250,000 per hospital) and reduces procedure turnaround time from 45 minutes to 15 minutes. Boston Scientific estimates total addressable market for single-use ureteroscopes at $1.2 billion globally.
User Case – Prostatic Urethral Lift Adoption (February 2026) : Teleflex’s UroLift system (implants that retract enlarged prostate lobes without cutting or heating) was featured in a new Medicare coverage decision (CMS) expanding access to office-based BPH treatment. Previously reimbursed only in ambulatory surgery centers (ASCs) and hospitals, the new policy (effective April 2026) allows UroLift in urology clinic procedure rooms, reducing patient out-of-pocket costs by 40-50%. Teleflex expects UroLift procedures to grow from 120,000 annually (2025) to 200,000 by 2028.
3. Competitive Landscape and Industry Characteristics
Key Players – Strategic Clusters
The market includes over 40 significant competitors, ranging from global conglomerates to specialized Chinese manufacturers. High-end capital equipment (endoscopes, surgical robots) is concentrated among Olympus, Karl Storz, Richard Wolf, Stryker, and Intuitive Surgical (da Vinci robotic system for urology). Implants and functional devices are dominated by Boston Scientific, Medtronic, Teleflex, and Coloplast. Stone management and consumables are more fragmented, with Cook Medical, BD, B. Braun, and ConvaTec competing alongside regional players like Hangzhou Kangji, Well Lead Medical, and PUSEN (China) and Zephyr Surgical Implants (Switzerland).
The China Factor
Chinese manufacturers – including Hangzhou Kangji Medical Instrument, Well Lead Medical, Scw Medicath, Zhanjiang Star Enterprise, Integral Medical Products, Shenzhen Hyde Medical, INT Medical, PUSEN, Tiansong Medical, and Shenda Endoscope – are rapidly gaining share in price-sensitive segments (stone baskets, guidewires, catheters, basic endoscopes). Their typical pricing is 30-50% below Western competitors, with gross margins of 20-30% versus Western margins of 40-60%. However, regulatory barriers (FDA 510(k), CE marking) and clinical evidence requirements remain challenges for international expansion beyond emerging markets.
Exclusive Industry Observation: The Business Model Evolution
Global Info Research identifies a critical structural shift: urology device manufacturers are transitioning from product-centric to solution-centric models. A decade ago, companies sold individual instruments (cystoscope, laser fiber, stone basket). Today, leading players offer integrated operating room solutions – combining capital equipment (endoscopy towers, laser generators), single-use consumables, procedure planning software, image-guided navigation, and multi-year service contracts. Boston Scientific’s “Stone Smart” platform bundles lithotripsy lasers, single-use scopes, retrieval devices, and data analytics to optimize stone clinic efficiency. This model increases customer switching costs (once a hospital adopts an integrated platform, switching to a competitor’s components is disruptive) and secures 5-7 year revenue streams.
Implication for Investors and Executives: Companies lacking integrated solutions (those selling only individual components) face margin erosion as customers demand bundled offerings. Strategic acquisitions of software, navigation, or AI companies are essential to build solution capabilities.
4. Technical Deep-Dive: AI, Robotics, and Image Guidance
AI-Assisted Diagnostics
Artificial intelligence is reducing diagnostic variability in urology. Siemens Healthineers and GE Healthcare have integrated AI algorithms into ultrasound and MRI systems for automated prostate volume measurement (critical for BPH treatment planning) and kidney stone detection (sensitivity 94% vs. 78% for unaided radiologists). In February 2026, the FDA cleared Medi-Globe’s AI cystoscopy software platform, which identifies suspicious bladder lesions in real-time (sensitivity 91%, specificity 85%), potentially reducing missed cancer diagnoses by 50%.
Robotic-Assisted Surgery
Intuitive Surgical remains dominant with the da Vinci system, used in over 60% of radical prostatectomies in the U.S. (approximately 80,000 procedures annually). However, EDAP TMS (France) launched the “Roboflex” system in March 2026 – a compact, single-use robotic ureteroscope for kidney stone treatment, priced at 150,000(versusdaVinci′s150,000(versusdaVinci′s2 million+). Roboflex has been adopted by 30 U.S. ambulatory surgery centers in its first 90 days. This represents a trend toward task-specific, lower-cost robots that expand beyond prostate cancer into high-volume procedures (stones, BPH).
Image-Guided Navigation
Stryker’s urology navigation system uses electromagnetic tracking to guide renal access during PCNL (percutaneous nephrolithotomy), reducing fluoroscopy time (radiation exposure) by 40% and improving first-pass stone clearance from 70% to 85%. Competitor Advanced MedTech (Singapore) launched a similar system in January 2026, priced 20% lower. Navigation is increasingly standard in advanced urology centers.
5. Technical Barrier – Supply Chain Vulnerabilities
Despite strong growth, the industry faces persistent headwinds. High R&D costs (optical systems, laser sources, robotic controls) require 50−100millioninvestmentsover5−7yearstobringamajorcapitalsystemtomarket.∗∗Regulatoryfragmentation∗∗remainsabarrier:FDA510(k)clearancecosts50−100millioninvestmentsover5−7yearstobringamajorcapitalsystemtomarket.∗∗Regulatoryfragmentation∗∗remainsabarrier:FDA510(k)clearancecosts500,000-1.5 million and takes 6-12 months, while EU MDR (Medical Device Regulation) compliance for Class IIb devices costs 1−2millionandtakes18−24months.ChineseNMPAregistrationaddsanother1−2millionandtakes18−24months.ChineseNMPAregistrationaddsanother200,000-500,000 and 12-18 months. Component supply constraints (medical-grade optical sensors, high-power laser diodes) – with only 3-4 qualified global suppliers – create lead times of 6-12 months for critical parts.
Intense pricing pressure affects mid- and low-end segments, particularly in Asia, the Middle East, and Latin America, where Chinese and Indian competitors undercut Western prices by 30-50%. Hospital procurement cycles are increasingly budget-constrained; U.S. hospitals face 2-3% annual operating margin pressure from reimbursement cuts under the Inflation Reduction Act and site-neutral payment policies. Raw material volatility (medical-grade stainless steel, titanium alloys, high-performance polymers) adds unpredictability to costs.
User Case – Supply Chain Rethinking (May 2026) : Following 2025 semiconductor and optical sensor shortages, Boston Scientific announced a $400 million investment to bring ureteroscope sensor assembly in-house (previously outsourced to a Japanese supplier). The new Minnesota facility will produce 3,000 sensors weekly and reduce lead times from 8 months to 6 weeks. CEO stated: “Supply chain resilience is now a competitive differentiator, not just a cost center.”
6. Future Outlook (2026-2031)
Base case (80% probability): 4.0-4.5% CAGR. Key assumptions: BPH, stone, and incontinence procedure volumes grow 3-5% annually in developed markets, 6-8% in emerging markets. Single-use device penetration continues (now 30% of ureteroscopy procedures, projected 50% by 2030). AI and navigation features become standard on 60% of new capital systems by 2028. Chinese domestic brands capture 15-20% of global consumables market (up from 5% today).
Upside scenario: Accelerated robotic adoption (task-specific, lower-cost platforms) could shift 20% of stone and BPH procedures from conventional to robotic by 2028, adding 1.5-2.0% to CAGR. Medicare expansion of office-based BPH treatment (already initiated) could add further 1-2%.
Downside risks: Prolonged hospital budget pressures (particularly in Europe with public debt constraints) could delay capital equipment replacement cycles. Trade restrictions on semiconductor and optical components (U.S.-China tensions) could disrupt supply. Regulatory backlogs at FDA and EU notified bodies (post-MDR implementation) could delay new product approvals by 6-12 months.
Strategic Recommendations for Stakeholders:
- For manufacturers: Invest in “razor-blade” models – competitive capital equipment pricing (low margin) followed by high-margin consumables, service, and software. Build integrated OR solutions to increase customer switching costs. Diversify supply chains (avoid single-source reliance on optical sensors, laser diodes) .
- For distributors: Focus on emerging markets (Southeast Asia, Middle East, Latin America) where urology procedure volumes are growing at 8-10% annually but device penetration remains low. Offer refurbished capital systems (30-40% discount to new) to budget-constrained hospitals.
- For investors: Favor companies with high consumable exposure (50%+ of revenue), dominant positions in high-growth segments (stone management, single-use endoscopes, implants), and diversified geographic revenue. Global Info Research estimates that consumable-heavy companies achieve 5-year revenue growth of 6-8% annually vs. 3-4% for equipment-heavy peers.
Conclusion: The urology devices market is undergoing structural transformation from capital equipment-driven growth to recurring consumable and solution-based revenue models. Aging populations, minimally invasive procedure adoption, and AI/robotic integration create tailwinds. However, supply chain resilience, regulatory navigation, and price competition remain challenges. The next 5-7 years will likely see consolidation as larger players acquire specialized technology companies – particularly in navigation, single-use scopes, and AI diagnostics – to complete their integrated portfolios.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
